ACP
VIR icon

Acuta Capital Partners’s Vir Biotechnology VIR Stock Holding History

Acuta Capital Partners’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-127,000
Closed -$5.2M – 54
2020
Q2 		$5.2M Buy
+127,000
New +$4.26M 1.5% 27

Other funds holding VIR

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
APF
Alaska Permanent Fund Juneau, Alaska $1.51B AUM 22.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $3.47B AUM 23.76% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Acuta Capital Partners's VIR Position: Q3 2020 in Review

Acuta Capital Partners sold out of Vir Biotechnology (VIR) in Q3 2020, closing a stake of 127,000 shares — an estimated $5.2M sold.

Acuta Capital Partners first reported a position in VIR in Q2 2020 and held it in 1 quarter. The position peaked at $5.2M in Q2 2020. 119 funds tracked by Wall St. Rank hold VIR as of Q3 2020.

  • Acuta Capital Partners reported no remaining Vir Biotechnology position as of Q3 2020 after selling out during the quarter.
  • Acuta Capital Partners sold 127,000 Vir Biotechnology shares in Q3 2020, an estimated $5.2M.
  • Acuta Capital Partners first reported a position in Vir Biotechnology in Q2 2020 and held it in 1 quarter.
  • Acuta Capital Partners's Vir Biotechnology position peaked at $5.2M in Q2 2020.
  • 119 funds tracked by Wall St. Rank held Vir Biotechnology as of Q3 2020.

Based on Acuta Capital Partners's 13F filing for Q3 2020, filed 16 Nov 2020.